| Literature DB >> 32500080 |
Soonkyu Hwang1, Namil Lee1, Suhyung Cho1, Bernhard Palsson2,3,4, Byung-Kwan Cho1,5.
Abstract
In nature, various enzymes govern diverse biochemical reactions through their specific three-dimensional structures, which have been harnessed to produce many useful bioactive compounds including clinical agents and commodity chemicals. Polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs) are particularly unique multifunctional enzymes that display modular organization. Individual modules incorporate their own specific substrates and collaborate to assemble complex polyketides or non-ribosomal polypeptides in a linear fashion. Due to the modular properties of PKSs and NRPSs, they have been attractive rational engineering targets for novel chemical production through the predictable modification of each moiety of the complex chemical through engineering of the cognate module. Thus, individual reactions of each module could be separated as a retro-biosynthetic biopart and repurposed to new biosynthetic pathways for the production of biofuels or commodity chemicals. Despite these potentials, repurposing attempts have often failed owing to impaired catalytic activity or the production of unintended products due to incompatible protein-protein interactions between the modules and structural perturbation of the enzyme. Recent advances in the structural, computational, and synthetic tools provide more opportunities for successful repurposing. In this review, we focused on the representative strategies and examples for the repurposing of modular PKSs and NRPSs, along with their advantages and current limitations. Thereafter, synthetic biology tools and perspectives were suggested for potential further advancement, including the rational and large-scale high-throughput approaches. Ultimately, the potential diverse reactions from modular PKSs and NRPSs would be leveraged to expand the reservoir of useful chemicals.Entities:
Keywords: domain; module; non-ribosomal peptide synthetase; polyketide synthase; repurposing
Year: 2020 PMID: 32500080 PMCID: PMC7242659 DOI: 10.3389/fmolb.2020.00087
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
FIGURE 1Domain architectures and mechanisms of polyketide chain extension in modular PKS. (A) Overall flow scheme of polyketide biosynthesis with different domain architectures of modules. Four types of loading modules load the different substrates according to involved domains (chemical examples were indicated). Next, the extender unit is selected and condensed to the growing chain one by one per elongation module for N cycles. Optional reductive domains (dashed circles) reduce the β-carbon group resulting in different X groups (indicated in red). Finally, the growing polyketide chain is cleaved by three different types of offloading domains in termination modules producing different products, including linear carboxylic acids, macrocyclic acids, olefins, aldehydes, and primary alcohols. (B) Mechanism of polyketide chain extension for the elongation module. (i) ACP–1 to KS translocation; the active site cysteine moiety of KS receives the growing polyketide chain of ACP–1. (ii) AT acylation; the cognate acyl unit is incorporated into the active site serine moiety of ATn to form the acyl-O-AT intermediate. (iii) AT to ACP transacylation; the acyl group of AT is transacylated to the ACP. (iv) KS to ACP chain elongation; KS catalyzes a decarboxylative Claisen condensation between the growing polyketide chain and the acyl extender unit of ACP for the chain extension. (v) Processing; the extender units of ACP are modified by a reductive loop or other additional domains. ACP, acyl carrier protein; AL, CoA ligase-type domain; AT, acyltransferase; CMT, C-methyltransferase; GNAT, GCN5 N-acetyltransferase-like domain; DH, dehydratase; ER, enoylreductase; KR, ketoreductase; KS, ketosynthase; KS, condensation-incompetent ketosynthase; R, reductive domain; ST, sulfotransferase; TE, thioesterase.
FIGURE 2Domain architectures and mechanisms of non-ribosomal peptide chain extension in modular NRPS. (A) Overall flow scheme of non-ribosomal peptide biosynthesis with different domain architectures of modules. Four representative types of loading modules load the different substrates according to the involved domains (chemical examples were indicated). Next, the extender unit is selected and condensed to the growing chain one by one per elongation module for N cycles. An example of optional processing domain is indicated by the dashed circles. Finally, the growing non-ribosomal peptide chain is cleaved by four representative types of offloading domains in termination modules, producing different products including linear peptides, macrocyclic peptides, aldehydes, and tetramate moieties. The terminal X group of the product from terminal R domain includes hydroxyl group (-OH), aldehyde group (-CHO), and other aldehyde derivatives (Barajas et al., 2015; Dan et al., 2019). (B) Mechanism of polyketide chain extension for the elongation module. (i) T–1 to C translocation; the growing non-ribosomal peptide chain linked to Ppant arm of T–1 domain translocates to the solvent channel of C domain donor site. (ii) A adenylation; the extender amino acid unit is activated by ATP to form aminoacyl-AMP in A domain. (iii) A to T thiolation; the aminoacyl-AMP intermediate of A is transferred to the Ppant arm of T domain to form aminoacyl thioester intermediate. (iv) T–1 to T condensation at C; the aminoacyl thioester intermediate of T domain is translocated to the solvent channel of C domain acceptor site, and the peptide bond formation between the growing peptide of T–1 domain and the amino acid extender unit of T domain elongates by adding one amino acid to the growing peptide. (v) Processing; the extender units of ACP are modified by an epimerase (E) domain or other additional domains. A, adenylation domain; C, condensation domain; C, terminal condensation domain; F, formylating domain; R, reductive domain; R*, R-like domain; T, thiolation domain; TE, thioesterase.
FIGURE 3Engineering scheme for modular PKS and NRPS. (A) Engineering strategies of PKSs. (B) Engineering strategies of NRPSs. Gray circles and red circles indicate the original and modified domains, respectively. Green, brown, blue, and purple blocks, shaped as lock-and-key models, are the docking domains for (A) and COM domains for (B), respectively. Linkers were indicated as the lines between the domains. In case of (iii) domain and module exchange, the exchangeable units are indicated at the right of the domains. The units indicated as bold characters are currently the best exchangeable units. PDB, precursor-directed biosynthesis.
Selected examples of the substrate exchange strategy.
| Precursor directed biosynthesis | 6-deoxyerythronolide B PKS | Native precursor propyl-CoA change to diketide precursor (SNPCs)/DEBS LM deletion | 15-fluoroethyl-6 deoxyerythronolide B | |
| Precursor directed biosynthesis | Rapamycin PKS | Native precursor 4,5-dihydroxycyclohex-1-enecarboxylic acid change to 21 analogs | Monocyclic aliphatic acids | |
| Precursor directed biosynthesis | Pyreudione NRPS | Native precursor | Pyreudione E to K | |
| Precursor directed biosynthesis | Iturin A NRPS | Native precursor | Fluorinated iturin A | |
| Mutasynthesis | Geldanamycin PKS | Native precursor 3-amino-5-hydroxybenzoic acid change to 18 analogs/3-amino-5-hydroxybenzoic acid (AHBA) biosynthetic gene deletion | Geldanamycin variants | |
| Mutasynthesis | DEBS1-soraphen hybrid PKS | Native precursor benzoate change to | Triketide lactone variants | |
| Mutasynthesis | FK506 PKS | Native precursor allylmalonyl CoA change to 4-methylpentanoic acid/ | 36-methyl-FK506 | |
| Mutasynthesis | Balhimycin NRPS | Native precursor β-OH-Tyr change to 3-Fht/ | Fluorobalhimycin | |
| Mutasynthesis | Balhimycin NRPS | Native precursor dihydroxyphenylglycine change to hydroxylated or methoxylated phenylglycines/ | Hydroxylated or methoxylated balhimycin | |
| Mutasynthesis | Salinosporamide NRPS | Native precursor 5′-CIDA change to 5′-FDA/ | Fluorosalinosporamide |
Selected examples of the substrate recognition domain mutagenesis.
| AT domain in module 4 of DEBS PKS | Methylmalonyl-CoA (YASH) to malonyl-CoA (HAFH) | Domain sequence alignment and structure-based selection | 6-desmethyl-6-dEB | |
| AT domain in module 3 of epothilone PKS | Both methylmalonyl, malonyl-CoA (HASH) to methylmalonyl-CoA (YASH) or malonyl-CoA (HAFH) | Domain sequence alignment | Triketide lactones derivatives | |
| AT domain in module 2 of DEBS PKS | Methylmalonyl-CoA (YASH) to non-natural propargyl, ethyl, allylmalonyl (VASH) | Domain sequence alignment and structure-based selection | Triketide lactones derivatives | |
| AT domain in module 6 of DEBS PKS | Methylmalonyl-CoA to diverse bulky extender units (Q,Y,S to A,G,R) | Structure-based selection | Propargyl, heptenyl, benzyl-SNAC incorporation | |
| AT domain in module 5,6 of pikromycin PKS | Methylmalonyl-CoA to propargyl, ethyl, allyl, butylmalonyl CoA (Y755V, Y753V) | Domain sequence alignment and Homology modeling | 10-dML analogs, narbonolide analogs | |
| AT domain in module 1 of avermectin PKS | 40 carboxylic acids to (2S)-methylbutyric acid (V222L or V222A) | Homology modeling | (2S)-methylbutyric acid (isolated module) | |
| AT domain in module 6 of DEBS PKS | Methylmalonyl-CoA (YASH) to non-natural alkynyl-modified extender unit (RASH) | Domain sequence alignment and saturation mutagenesis | 10-dML analogs | |
| A domain of module 2 of surfactin NRPS | Domain sequence alignment and Homology modeling | [Asn5]surfactin | ||
| A domain of module 10 of CDA NRPS | Domain sequence alignment | CDA4a-10mQ | ||
| A domain of module 3 of Fusaricidins NRPS | Domain sequence alignment | Fusaricidin analog (LI-F07) | ||
| A domain of module 1 of Anabaenopeptin NRPS | Structure-based selection | Novel anabaenopeptin analog, clickable | ||
| A domain of module 1 of gramicidin S NRPS | Structure-based selection and saturation mutagenesis | Propargylated DKP, clickable | ||
| A domain of module 1 of syringomycin NRPS | A domain of | Domain sequence alignment, directed evolution (2 rounds), and iron growth selection | Enterobactin derivatives | |
| A domain of AdmK of andrimid NRPS/PKS hybrid | Domain sequence alignment, directed evolution, and high-throughput LC-MS/MS | Andrimid derivatives | ||
| A domain of module 1 of tyrocidine NRPS | Domain sequence alignment, directed evolution, and PPi exchange assay | Tyrocidine derivatives | ||
| A domain of module 1 of bacillibactin NRPS | 2,3-dihydroxybenzoic acid to 3-hydroxybenzoic acid and 2-aminobenzoic acid (four sites mutations) | Domain sequence alignment, directed evolution, and yeast surface display with FACS | 3-hydroxybenzoic acid and 2-aminobenzoic acid (isolated module) |
Selected examples of domain or module exchange of modular PKS.
| AT-PAL1 | AT domain in module 1 of DEBS PKS | Methylmalonyl to malonyl CoA specific/rapamycin AT domain in module 2 exchange/N,C-term RE site splicing | Domain sequence alignment | Two novel triketide lactones | |
| AT-PAL1-PAL2 | AT domain in module 6 of DEBS PKS | Methylmalonyl to methylmalonyl or malonyl CoA specific/RAPS AT2, DEBS AT4, DEBS AT5 exchange/interdomain region RE site splicing | Domain sequence alignment | Triketide lactones derivatives | |
| AT-PAL1 | AT domain in module 4 of DEBS PKS | Methylmalonyl to malonyl CoA specific/rapamycin AT domain in module 2 exchange/N,C-term RE site splicing | Domain sequence alignment | 6-desmethyl erythromycin D | |
| AT-PAL1 | AT domain in module 4 of DEBS PKS | Methylmalonyl to ethylmalonyl CoA specific/niddamycin AT domain in module 5 exchange/N,C-term RE site splicing | Domain sequence alignment | 6-desmethyl-6-ethylerythromycin A | |
| AT-PAL1-PAL2 | AT domain in module 1-5,7 of geldanamycin PKS | Methylmalonyl or methoxymalonyl to malonyl CoA specific/rapamycin AT domain in module 2,14 exchange/N,C-term RE site splicing | Domain sequence alignment | Geldanamycin derivatives | |
| AT-ACP | LM (AT-ACP) of DEBS PKS | Methylmalonyl or malonyl CoA to 40 carboxylic acids specific/AVES LM (AT-ACP) exchange/ACP C-term region splicing | Domain sequence alignment | Novel antibiotic erythromycins | |
| KS | LM (KS | Malonyl to Methylmalonyl CoA specific/Platenolide LM (KS | Domain sequence alignment | 16-methyl platenollde I | |
| KAL-AT-PAL1 | AT domain in module 6 of DEBS PKS, AT domain in module 1 of β-lipomycin PKS | Methylmalonyl to methylmalonyl or malonyl CoA specific/epothilone AT domain in module 4 exchange, other various AT domains exchange/KAL-AT-PAL1 | Domain sequence alignment and structure-based selection | 3-hydroxycarboxylic Acid, short-chain ketones | |
| KS-AT-KR-ACP | Insertion between module 1,2 (KS-AT-KR-ACP) of DEBS PKS | Methylmalonyl, malonyl CoA specific added/rapamycin module 2,5 (KS-AT-KR-ACP, AT-KR-ACP-KS) insertion/KS N-term, C-term RE site splicing | Domain sequence alignment | Novel octaketide macrolactones | |
| KS-AT-ACP, multi-modules | Modules of DEBS PKS | Same specificity/M1-M3, M1-M6, M1-RifM5, M2 to RifM5/Native RE site, conserved region of interpolypeptide linker | Domain sequence alignment | Triketide lactones derivatives | |
| KS-AT-ACP | Modules of DEBS, soraphen, epothilone, geldanamycin, rifamycin, rapamycin, pikromycin, leptomycin PKS | Two module combinatorial biosynthesis of 14 module of 8 PKS/Conserved region of KS N-term and ACP C-term RE spicing | Domain sequence alignment | Triketide lactones derivatives | |
| KS-AT-ACP | Modules of DEBS 1,2,3 PKS | Methylmalonyl to propionyl, methylmalonyl, malonyl CoA specific/3 module combinatorial biosynthesis/conserved region of interpolypeptide linker | Domain sequence alignment | Triketide lactones derivatives | |
| AT-DH-KR-ACP-KS | Module 2 of neoaureothin PKS | Deletion of methylmalonyl CoA specific module 2/KS-AT linker conserved region and docking domain of ACP RE splicing | Domain sequence alignment | Homoaureothin | |
| KS-AT-ACP, KS-AT | Module 6 of DEBS PKS | Methylmalonyl-CoA to methylmalonyl or malonyl CoA specific/module 2,3,5 of DEBS PKS exchange/docking domain exchange to SYNZIP | Domain sequence alignment and structure-based selection | Triketide lactones derivatives |
Selected examples of domain or module exchange of modular NRPS.
| A | A domain in module 7 of surfactin NRPS | Domain sequence alignment | Five different surfactin variants | ||
| A | A domain in module 3 of hormaomycin NRPS | (β-Me)Phe to | Homology modeling | Altered substrates (A domain assay) | |
| A, T-C-A | A domain in module 8,9 of tyrocidine NRPS | Domain sequence alignment | Dipeptides (isolated module) | ||
| A, C-A | A domain in module 10 of pyoverdine NRPS | Domain sequence alignment | Pyoverdine derivatives | ||
| A-T | A domain in module 2 of actinomycin NRPS | Domain sequence alignment | Acyl-threonine–MeVal (isolated module) | ||
| C-A-T, C-A-T-E | Modules 8-13 of daptomycin NRPS | Domain sequence alignment | Daptomycin derivatives | ||
| C-A-T, C-A-T-E | Modules 2,3,8,11,12,13 of A54145 NRPS | Domain sequence alignment | A54145 derivatives | ||
| C-A-T-C | Modules 1,5 of surfactin NRPS | Domain sequence alignment | Recombinant lipopeptides | ||
| C-A + T-E | Insertion between module 4 and 5 of balhimycin NRPS | Domain sequence alignment | Balhimycin derivatives | ||
| A-T-C | Modules of xenotetrapeptide NRPS | Various changes/recombination of XtpS, GxpS, KolS, AmbS, GarS, GrsB, BicA/C-A linker region (WNATE) splicing. | Domain sequence alignment and structure-based selection | Xenotetrapeptides | |
| C | Modules of xenotetrapeptide NRPS | Various changes/recombination of XtpS, GxpS, KolS, AmbS, GarS, GrsB, BicA, SrfA, GrsAB, TycC, XeyS, Pax, others/C | Domain sequence alignment and structure-based selection | Xenotetrapeptides | |
| C-A-T-E, multi-modules | Modules 4,5,6 of surfactin NRPS | Domain sequence alignment | Surfactin derivatives |
Selected examples of processing and offloading domain engineering.
| KR domain in module 6 of DEBS PKS | KR inactivation/Y159F, S146A, K163E mutation | Domain sequence alignment and Homology modeling | 3-Keto derivative of 6-deoxyerythronolide B | |
| KR domain in module 2 of DEBS PKS | A1-type KR change to eight A2-type KR domains (amphotericin KR1, KR11, concanamycin KR4, KR10, elaiophylin KR4, oligomycin KR5, pimaricin KR7, candicidin KR13) and six B2-type KRs (DEBS KR1, lankamycin KR1, pikromycin KR1, lasalocid KR7, ECO-02301 KR19, stambomycin KR21)/AT-KR linker and KR-ACP linker RE splicing | Domain sequence alignment | Epimerized triketide lactones | |
| KR domain in module 1 of lipomycin PKS | A2-type KR change to A1-type amphotericin KR2 (or +DE2), and B1-type concanamycin KR2 (or +DE2)/post AT linker before DE and KR-ACP linker RE splicing | Domain sequence alignment and structure-based selection | ||
| KR domain in module 2 of DEBS PKS | A1-type KR change to A2-type amphotericin KR2 and amphotericin KR11 with cognate DE/post AT linker before DE and KR-ACP linker RE splicing | Domain sequence alignment and structure-based selection | 2D,2L-triketide lactone, ketolactones | |
| DH domain in module 18 and KR domain in module 21 of FR-008 PKS | KR and DH inactivation/Y1526F for KR21, H3084Y for DH18. | Domain sequence alignment | FR-008-V, -III, and -VI | |
| ER domain in module 4 of DEBS PKS | ER stereochemistry altered/Y52V for ER4 domain. | Domain sequence alignment and homology modeling | Triketide lactone with S to R methyl branch configuration switched | |
| KR domain in module 1 of borrelidin PKS | BorKR1 to Reductive loop of SpnB of spinosyn PKS and SpnBDH1 (in | Domain sequence alignment, structure-based selection and Ppant ejection | Adipic acid | |
| TE domain in module 9 of tautomycetin PKS | Linear release change to macrocyclization by using TE domain in module 6 of pikromycin/TMC TE linker downstream splicing | Domain sequence alignment | Cyclized tautomycetin analog | |
| E domain in module 4 of tyrocidine NRPS | Domain sequence alignment | |||
| MT domain in module 2 of bassianolide NRPS, module 2 of beauvericin NRPS | Domain sequence information | |||
| MT domain insertion to module 6 of echinomycin NRPS | Domain sequence alignment | |||
| Tyrocidine derivative with | Domain sequence alignment, combinatorial solid-phase chemistry | Cyclized tyrocidine analogs |
FIGURE 4Representative repurposing examples of modular PKS and NRPS for de novo biosynthetic pathways. (A) Repurposing the PKS domains and modules for the production of short-chain ketones. Green circles are the domains in module 1 of β-lipomycin PKS (LIPS M1), red circles are the AT domains in module 1 of borrelidin PKS (BORS A1), gray circles with the red crossed line are the inactivated KR domain (KR null), and the blue circles are the TE domain of DEBS PKS. (B) Repurposing the PKS domains and modules for the production of adipic acid. Green circles are the domains in module 1 of borrelidin PKS (BORS M1), red circles are the KR and ER domain in SpnB module of spinosyn PKS (SpnB KR, ER), and the blue circles are the TE domain of DEBS PKS. (C) Repurposing the NRPS module for the production of thiopyrazines. NRPS325 module of ATEG00325 PKS-NRPS hybrid megasynthetase was isolated (red circles) to promote the reaction for the thiopyrazine production itself. (D) Repurposing the NRPS domain for the production of paclitaxel derivatives. The A or A-T didomain in TycA module of tyrocidine A PKS was isolated (red circles) to be repurposed for the production of phenylalanyl-, phenylisoserinyl-, arylisoserinyl-CoAs, which are the precursors of the paclitaxel derivatives; X, NH2 or H; Y, H or OH; Z, NH2 or H.
Selected examples of modular PKS and NRPS repurposing for de novo biosynthetic pathways.
| Bio-based fuel | 3-hydroxy acids | LipPks1 from lipomycin PKS + TE from erythromycin PKS | ||
| Bio-based fuel | 3-hydroxy acids | LipPks1 from lipomycin PKS + TE from erythromycin PKS | ||
| Bio-based fuel | Short chain ketones | AT swapped LipPks1 from lipomycin PKS + TE from erythromycin PKS + KR null | ||
| Bio-based fuel | Short chain ketones | AT swapped LipPks1 from lipomycin PKS + TE from erythromycin PKS + KR null + truncated N-terminal linker of KAL | ||
| Industrial chemicals | Adipic acids | Reductive loop swapped BolLM-BorMod1 from borrelidin PKS + TE from erythromycin PKS | ||
| Industrial chemicals | Triketide lactones | 154 designed bimodular PKSs based on 14 modules form eight PKSs | ||
| Industrial chemicals | Triketide lactones | 54 designed trimodular PKSs | ||
| Industrial chemicals | Triketide lactones | DEBS1 + TE from erythromycin PKS | ||
| Industrial chemicals | Triketide lactones | DEBS1 + TE from erythromycin PKS | ||
| Industrial chemicals | Triketide lactones | Mod2 of DEBS1 + TE from erythromycin PKS | ||
| Potentially useful chemical | Thiopyrazine | Isolated NRPS module (NRPS325) of isoflavipucine PKS-NRPS megasynthetase (ATEG00325) | ||
| Anticancer | Paclitaxel derivatives | Isolated NRPS domain (A or A-T domain) of tyrocidine synthetase TycA module + semisynthesis |
FIGURE 5Roadmap for repurposing modular PKS and NRPS. Design-build-test-learn cycle with the tools for each step was illustrated.